Bio-Immunozyme Forte 90T

NPN: 80045768

Item Code: 6300

Quantity: 90 tablets

Description: Immune Support

Indications: Broad-spectrum vitamin, mineral, trace element, neonatal glandular (adrenal, thymus, spleen, liver, pancreas, parotid, lymph, placenta), herbal (Echinacea, Capsicum), proteolytic enzyme (trypsin, alpha chymotrypsin), vegetable culture antioxidant enzymes SOD and catalase, bioflavonoid, chlorophyll formulation to consider support immune function and for chronic immune conditions, possibly hepatitis.
Ingredients: See Product Label below.

Suggestion: Two (2) tablets each day as a dietary supplement or as otherwise directed by a health care professional.

References: Independent research and additional information

Goldstein AL, Cohen GH, Thurman GB, Hooper JA, Rossio JL. Regulation of immune balance by thymosin: potential role in the development of suppressor T-cells. Adv Exp Med Biol. 1976;66:221-8

Aiuti F, Sirianni MC, Paganelli R, Stella A, Turbessi G, Fiorilli M. A placebo-controlled trial of thymic hormone treatment of recurrent herpes simplex labialis infection in immunodeficient hosts. Int J Clin Pharmacol Ther Toxicol. 1983 Feb;21( 2):81-6

Pandolfi F, Quinti I, Montella F, Voci MC, Schipani A, Urasia G, Aiuti F. T-dependent immunity in aged humans. II. Clinical and immunological evaluation after three months of administering a thymic extract. Thymus. 1983 Apr;5( 3-4):235-40.

Rimoldi R, Brunetta F, Fioretti M, Bandera M, Ghione M. Thymostimulin in malignant pleural effusions. Int J Tissue React. 1984;6( 1):53-5.

Azizi E, Brenner HJ, Shoham J. Postsurgical adjuvant treatment of malignant melanoma patients by the thymic factor thymostimulin. Arzneimittelforschung. 1984;34( 9):1043-7

Hegarty JE, Nouri Aria KT, Eddleston AL, Williams R. Controlled trial of a thymic hormone extract ( Thymostimulin) in \'autoimmune\' chronic active hepatitis. Gut. 1984 Mar;25( 3):279-83.

Romeo F, Arcoria D, Palmisano L, Polosa P. Effectiveness of thymostimulin treatment in hepatitis B surface antigen-positive chronic active liver disease. Results of a randomized clinical trial. Arzneimittelforschung. 1985;35( 8):1317-22.

Galli M, Crocchiolo P, Negri C, Caredda F, Lazzarin A, Moroni M. Attempt to treat acute type B hepatitis with an orally administered thymic extract ( thymomodulin): preliminary results. Drugs Exp Clin Res. 1985;11( 9):665-9.

Pivetti-Pezzi P, De Liso P, Tamburi S, Luzi G, Sirianni MC, Palmisano L, Aiuti F. Thymic factor therapy for herpetic keratitis. Ann Ophthalmol. 1985 Jun;17( 6):327-31.

Fiocchi A, Borella E, Riva E, Arensi D, Travaglini P, Cazzola P, Giovannini M. A double-blind clinical trial for the evaluation of the therapeutical effectiveness of a calf thymus derivative ( Thymomodulin) in children with recurrent respiratory infections. Thymus. 1986;8( 6):331-9.

Schiavon M, Chiarelli A, Lohr G, Mazzoleni F. Thymostimulin in the antiinfectious treatment in patients with burns. Arzneimittelforschung. 1987 May;37( 5):557-60.

Liberati AM, Ballatori E, Fizzotti M, Schippa M, Cini L, Cinieri S, Proietti MG, Di Marzio R, Senatore M, Grignani F. A randomized trial to evaluate the immunorestorative properties of thymostimulin in patients with Hodgkin\'s disease in complete remission. Cancer Immunol Immunother. 1988;26( 1):87-93

Iaffaioli RV, Frasci G, Tortora G, Ciardiello F, Nuzzo F, Scala S, Pacelli R, Bianco AR. Effect of thymic extract \'thymostimulin\' on the incidence of infections and myelotoxicity during adjuvant chemotherapy for breast cancer. Thymus. 1988-89;12( 2):69-75

Chisesi T, Capnist G, Rancan L, Pellizzari G, Vespignani M. The effect of thymic substances on T circulating cells of patients treated for Hodgkin\'s disease. J Biol Regul Homeost Agents. 1988 Oct-Dec;2( 4):193-8

Macchiarini P, Danesi R, Del Tacca M, Angeletti CA. Effects of thymostimulin on chemotherapy-induced toxicity and long-term survival in small cell lung cancer patients. Anticancer Res. 1989 Jan-Feb;9( 1):193-6

Macchiarini P, Danesi R, Del Tacca M, Angeletti CA. Effects of thymostimulin on chemotherapy-induced toxicity and long-term survival in small cell lung cancer patients. Anticancer Res. 1989 Jan-Feb;9( 1):193-6

Chachoua A, Green MD, Valentine F, Muggia FM. Phase I/II trial of thymostimulin in opportunistic infections of the acquired immune deficiency syndrome. Cancer Invest. 1989;7( 3):225-9.